Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical stage vaccine company Immunovaccine has reported positive results from ongoing study of DepoVax-based anthrax vaccines, as part of an ongoing bio-defense research program.
Subscribe to our email newsletter
According to the study data, DepoVax-based vaccines offer rapid and long lasting immune response compared to the licensed anthrax vaccine BioThrax.
Immunovaccine chief science officer Dr. Marc Mansour said the study demonstrated that DepoVax-formulated vaccines generate toxin neutralizing antibodies with one dose.
"These findings suggest the potential for DepoVax to enable the development of an effective and safe next generation anthrax vaccine," Mansour added.
DepoVax-formulated anthrax vaccines established the potential to induce toxin neutralizing antibodies with a single dose and were shown to be well-tolerated with no safety concerns in non human primate study.
Studies with NIAID Preclinical Services, scheduled to begin in 2013, will assess the ability of neutralizing antibody responses induced by a DepoVax-based vaccine to protect animals from anthrax.